A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

BACKGROUND: An inactivated quadrivalent influenza vaccine (QIV) was recently licenced in the US as a thimerosal-free formulation presented in a pre-filled syringe. A multidose presentation is preferred in some settings due to reduced acquisition and cold storage costs. We assessed the immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Varsha K, Chandrasekaran, Vijayalakshmi, Wang, Long, Li, Ping, Liu, Aixue, Innis, Bruce L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995899/
https://www.ncbi.nlm.nih.gov/pubmed/24606983
http://dx.doi.org/10.1186/1471-2334-14-133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995899/
https://www.ncbi.nlm.nih.gov/pubmed/24606983
http://dx.doi.org/10.1186/1471-2334-14-133

Ejemplares similares